<DOC>
	<DOCNO>NCT02203643</DOCNO>
	<brief_summary>This study evaluate safety efficacy carfilzomib combine cyclophosphamide dexamethasone ( CCyd ) lenalidomide dexamethasone ( CRd ) follow autologous transplantation ASCT 12 cycle carfilzomib combine dexamethasone lenalidomide patient eligible ASCT newly diagnose multiple myeloma . As secondary endpoint study evaluate best maintenance treatment lenalidomide lenalidomide combine carfilzomib . Four hundred seventy-seven patient , male female age &gt; 18 year , enrol several site , take part study . The duration study approximately 5 year .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Carfilzomib Combined With Cyclophosphamide Dexamethasone ( CCyd ) Lenalidomide Dex ( CRd ) Followed ASCT 12 Cycles Carf Combined With Dex Len Patients Eligible ASCT With Newly Diagnosed Multiple Myeloma .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age ≥ 18 year Newly diagnose MM base standard CRAB criterion ( see appendix B ) . Patient &lt; 65 year eligible ASCT . Patient measurable disease accord IMWG ( International Myeloma Working Group ) criterion . Patient give voluntary write informed consent . Patient agree use acceptable method contraception . Patient Karnofsky performance status ≥ 60 % Pretreatment clinical laboratory value within 30 day enrolment : Platelet count ≥50 x 109/L ( ≥30 x 109 /L myeloma involvement bone marrow &gt; 50 % ) Absolute neutrophil count ( ANC ) ≥ 1 x 109/L without use growth factor Corrected serum calcium ≤14 mg/dL ( 3.5 mmol/L ) Alanine transaminase ( ALT ) : ≤ 3 x Upper Limit Normal ( ULN ) Total bilirubin : ≤ 2 x ULN Calculated measure creatinine clearance : ≥ 30 mL/minute . LVEF≥40 % . 2D transthoracic echocardiogram ( ECHO ) prefer method evaluation . Multigated Acquisition Scan ( MUGA ) acceptable ECHO available Life expectancy ≥ 3 month Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid &lt; equivalent dexamethasone 40 mg/day 4 day ) Patients nonsecretory MM unless serum freelight chain present ratio abnormal plasmocytoma minimum large diameter &gt; 2 cm Patients ineligible autologous transplantation Pregnant lactating female Presence : Clinical active infectious hepatitis type A , B , C HIV Acute active infection require antibiotic infiltrative pulmonary disease Myocardial infarction unstable angina ≤ 4 month clinically significant heart disease Peripheral neuropathy neuropathic pain grade 2 high , defined National Cancer Institute Common Toxicity Criteria ( NCI CTC ) 4.0 Known history allergy Captisol ® ( cyclodextrin derivative use solubilize carfilzomib ) Contraindication require drug supportive treatment Invasive malignancy within past 3 year Serious medical condition , laboratory abnormality psychiatric illness prevent subject enrolment place subject unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>